Article Text
Commentary
2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials
Statistics from Altmetric.com
Footnotes
-
Contributors All authors contributed to the composition and/or critical review of the manuscript.
-
Competing interests MG is a consultant for Covidien/ev3 and serves as a co-principal investigator for SWIFT-PRIME and ESCAPE trials. AST has research grants or consulting agreements with Stryker, Microvention, Penumbra and Codman. JM serves as a consultant for Lazarus Effect and Nfocus and has investor interests in Blockade Medical. DSL serves as a consultant for Stryker and Covidien. AMD has received honoraria from Covidien. All other authors have no disclosures to report.
-
Provenance and peer review Not commissioned; internally peer reviewed.